Industry news

  • 19 June 2018

    Russia is ready to supply insulin to Bulgaria

    GMP News

    The time has come to reduce imports from abroad and start establishing contacts with neighbors,” said Ivan Zarubin, acting Trade Representative of the Russian Federation in the Republic of Bulgaria, speaking at the Medicine and Pharmacy 2018, a Bulgarian-Russian business forum held in Sofia on June 13.

  • 19 June 2018

    Construction of a new pharmaceutical plant started in Usolye-Sibirskoye

    GMP News

    An official ceremony marking the launch of construction was held at the site of future plant for active pharmaceutical substances and finished medicinal products of Pharmasyntez-Chemie in Usolye-Sibirskoye on June 15.

  • 18 June 2018

    The cost of drug labeling implementation is considered as reasonable

    GMP News

    According to market participants, the costs of drug manufacturers on mandatory implementation of labeling by 2020 will not increase the cost of drugs. “We do not expect that the cost of medicinal products manufactured by Stada will rise following the implementation of drug labeling,” said Ivan Glushkov, Director of External Relations Department at Stada Russia.

  • 18 June 2018

    Russian nationwide network of biobanks will help to develop new drugs

    GMP News

    New drugs and treatments development requires experiments on animals and humans. However, many problems can be solved just by studying the samples of human tissues outside the human body. To this end, Russia is establishing a nationwide network of biobanks.

  • 15 June 2018

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 90,000 shares of its common stock to two new employees, with a grant date of  June 14, 2018 .

  • 15 June 2018

    New Russian Cancer Drug Increases Survival Rate of Mice by Over 50%

    Remedium

    A group of researchers from the National University of Science and Technology MISIS (NUST MISIS) and the Pirogov Russian National Research Medical University have conducted preclinical studies of a new cancer drug based on magnetic nanoparticles.

  • 15 June 2018

    Indian company wants to build a pharmaceutical plant in Kursk

    GMP News

    On June 9, 15 new contracts and agreements were signed as part of the business program of the Kursk Korenskaya Fair. One of the signed documents was the memorandum of understanding on cooperation between the city of Kursk and ZEE Laboratories Ltd., an Indian pharmaceutical company.

  • 14 June 2018

    Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced completion of patient enrollment in a Phase 3 clinical trial (“SAPPHIRE”) of suprachoroidal CLS-TA used in combination with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) for the treatment of Retinal Vein Occlusion (“RVO”).

  • 13 June 2018

    2 studies show CRISPR might drive up cancer risk in edited cells

    Amirah Al Idrus / FierceBiotech

    Off-target, or unintended, editing is a key safety concern of CRISPR-Cas9, as it can lead to cancer and other side effects. Two new studies show that CRISPR editing could raise the risk of targeted cells—those being edited to treat disease—developing tumors.

  • 13 June 2018

    European Commission proposed a new research and innovation program

    GMP News

    For the next long-term EU budget 2021-2027, the Commission proposed €100 billion for research and innovation. The new programme – Horizon Europe – will build on the achievements and success of the previous research and innovation programme (Horizon 2020) and keep the EU at the forefront of global research and innovation.

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news